1 September 2024

Starpharma to present DEP® at Radiopharmaceuticals Summit (ASX Announcement)

Melbourne, Australia; 6 December 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it is presenting at the Targeted Radiopharmaceuticals Summit Europe, having been invited to present at the specialist radiotheranostics conference being held in Berlin, Germany, from 5 to 7 December 2023.

The Targeted Radiopharmaceuticals Summit also includes speakers from Novartis, Bayer, Bicycle Therapeutics, AstraZeneca, Bristol-Myers Squibb, Precirix, Telix, and Fusion Pharmaceuticals. The Summit brings together professionals to provide insights into the research, development, and commercialisation of radiopharmaceuticals, including novel targets and combination therapies.

Starpharma’s Vice President of Development and Regulatory Affairs, Dr Jeremy Paull, will deliver a presentation on the application of Starpharma’s DEP® platform for precision cancer radiotheranostics, including:

  • the application, versatility, and benefits of the DEP® platform for targeted delivery of radiotheranostics; and
  • an overview of Starpharma’s two DEP® HER2-targeted radiotheranostic products, DEP® HER2-zirconium and DEP® HER2-lutetium.

Starpharma recently reported data on DEP® HER2-zirconium, a HER2-targeted radiodiagnostic candidate, demonstrating excellent tumour accumulation, a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake in a HER+ breast cancer model. Starpharma’s radiotherapeutic product, DEP® HER2-lutetium, has shown excellent anticancer activity, outperforming Herceptin® labelled with lutetium, in a human breast cancer model. These products are designed to assist in improving the diagnosis, staging, monitoring, and treatment of HER2+ cancers, which include breast and upper gastro-intestinal cancers. The data reported in the presentation have been generated from studies conducted in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS) and the University of Queensland.

The conference presentation, ‘Branching Out: DEP® Dendrimer Nanoparticles as a Versatile Platform for Precision Cancer Radiotheranostics’, will take place on 6 December 2023 in Berlin as part of the Novel Targets stream.

View/download the ASX Announcement: Starpharma to present DEP® at Radiopharmaceuticals Summit.

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.